联系方式:Changzheng.lu@szbl.ac.cn
卢长征博士从2012年开始进入肿瘤免疫领域,博士阶段与Seven& Eight Biopharma合作研发抗肿瘤免疫药物。所研药物已申请7项美国专利,先后在欧美开展I、II期临床试验,现已被默沙东前研发掌门人Roger M Perlmutter博士领导的Eikon Therapeutics收购。2016年加入美国西南医学中心进行博士后训练,研究课题之一发表在Cancer Cell 杂志(被欧洲癌症研究学会评为2020年度十大癌症研究论文),解析了DNA错配修复缺失型(dMMR)肿瘤响应和抵抗PD-1抗体治疗的机制,揭示了肿瘤细胞自身的cGAS-STING通路对于肿瘤微环境中T细胞浸润水平的调控作用,为精准免疫治疗提供了新的标志物。获得包括2021年度国家优秀青年科学基金项目(海外),国自然面上,深圳湾实验室重大(培育)项目和医药转化概念验证项目等基金项目的资助。
Huang, Y.#, Lu, C.#, Wang, H., ... & Li, G. M. (2023). DNAJA2 deficiency activates cGAS-STING pathway via the induction of aberrant mitosis and chromosome instability. Nature Communications,14(1):5246.
Yitong Cai, Anli Zhang, Changzheng Lu*. (2022). Precision intervention of cell type-specific targeting is required for future cancer immunotherapy. Medical Review, 2(6), 553-554.
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., ... & Fu, Y. X. (2021). DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity. Cancer Cell, 39(1), 96-108.This paper is previewed by Cancer Cell (https://www.cell.com/cancer-cell/fulltext/S1535-6108(20)30664-4); Highlighted by Science Signaling (https://stke.sciencemag.org/content/14/666/eabg5661.full); A highly cited paper by Web of Science.
Guan, J.#, Lu, C.#, Jin, Q., Lu, H., Chen, X., Tian, L., ... & Li, G. M. (2021). MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell, 39(1), 109-121. A highly cited paper by Web of Science.